The global Fecal Calprotectin Test Market is estimated to be valued at US$ 140.6 Mn in 2023 and is expected to exhibit a CAGR of 12.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Fecal calprotectin test is a non-invasive diagnostic test used to detect and monitor inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis. The test measures the level of calprotectin protein in feces, which helps determine the presence and severity of bowel inflammation. Higher levels of calprotectin indicate active inflammation in the intestinal tract.
Market key trends:
One of the key trends in the fecal calprotectin test market is the advent of rapid home-based sample collection kits. Companies are developing easy to use rapid test kits that can detect fecal calprotectin levels within minutes from a small stool sample collected at home. This reduces the need for time-consuming and inconvenient visits to laboratories or clinics for sample collection. Home testing increases accessibility and compliance for regular screening and monitoring of inflammatory bowel conditions.
Market key trends:
The fecal calprotectin test market has seen increased demand in recent years due to its role in detecting and monitoring inflammatory bowel diseases (IBD). This non-invasive diagnostic tool measures the level of calprotectin in stool samples, which is a protein released by neutrophils during inflammation in the gastrointestinal tract. Higher levels of calprotectin are strongly associated with gastrointestinal inflammation. Key players are focused on developing rapid point-of-care tests to provide timely diagnosis and management of IBD.
SWOT Analysis
Strengths: Non-invasive nature makes it more comfortable for patients compared to endoscopy. Valuable marker for detecting intestinal inflammation related to IBD.
Weaknesses: Cannot distinguish between different types of IBD. Other factors like infection can also increase calprotectin levels.
Opportunities: Growing IBD patient pool globally increases testing demand. Developing economies yet to widely adopt this testing.
Threats: Alternative emerging biomarkers may diminish reliance on calprotectin. Strict regulatory landscape for diagnostic tests.
Key Takeaways
The Global Fecal Calprotectin Test Market Size is expected to witness high growth at a CAGR of 12.3% over the forecast period of 2023 to 2030 due to increasing IBD prevalence globally. The North American region currently dominates the market owing to high awareness and favorable reimbursements.
The global fecal calprotectin test market size for 2023 is estimated to be US$ 140.6 Mn. Calprotectin level testing helps physicians in identifying patients requiring additional therapy or endoscopy to diagnose IBD or monitor response to treatment as higher levels are strongly associated with gastrointestinal inflammation.
Key players operating in the fecal calprotectin test market include Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv Diagnostics Gmbh, Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc., RayBiotech, Inc., and ALPCO. These established players are focusing on expanding their presence and product portfolios in high growth markets through new product launches, partnerships and acquisitions.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
